Dizhe Pharmaceutical received a 120 million yuan investment from Jiangsu Zhanxin Wuxi Biomedical Fund

　　Recently, Dizhe Pharmaceutical (stock code: 688192), a biopharmaceutical listed company on the Science and Technology Innovation Board, received a subscription investment of 120 million yuan from the Jiangsu Wuxi Biopharmaceutical Industry Special Mother Fund (Limited Partnership) through a private placement. This is also the first direct investment project completed by the parent fund. Dizhe Pharmaceutical raised a total of 1.8 billion yuan this time, with other investors including Taikang Asset Management, Penghua Fund, UBS, etc. The funds will be used to support the clinical promotion of the company's self-developed pipeline and the construction of an international standard innovative drug industrialization platform.

　　Dizhe (Jiangsu) Pharmaceutical Co., Ltd. was established in 2017 and is headquartered in Wuxi, Jiangsu. It focuses on the research, development, and commercialization of Class 1 innovative drugs in the fields of malignant tumors and immune diseases. The company was formerly known as AstraZeneca's only global cancer translational science research center. Based on industry-leading translational science and new drug molecular design and screening technology platforms, it has established six globally competitive product pipelines, including sunitinib (trade name: sunitinib) ®）、 Golixitinib (trade name: Gao Ruizhe) ®） Two globally innovative products have been successfully launched and included in the national medical insurance catalog. The company has a rich product matrix that combines high growth and innovative explosive power.

　　The Jiangsu Wuxi Biomedical Industry Special Mother Fund (Limited Partnership) has a scale of 4 billion yuan, with the goal of high-quality development of the entire industry chain. The fund enriches the five in one development model of "leading direction+leading enterprises+professional funds+research and development institutions+service platforms" in Wuxi, further promoting the upgrading of the tin free biopharmaceutical industry and the expansion of the industry chain, and helping Wuxi build an efficient energy gathering industry ecosystem for biopharmaceuticals. Xi Venture Capital has long been deeply involved in strategic emerging industries such as biomedicine, actively serving the construction of Wuxi's "465" modern industrial cluster, focusing on advantageous industries, fully leveraging the leverage effect of the Zhanxin Mother Fund, supporting the development of science and technology innovation enterprises, accelerating the aggregation of Wuxi's biopharmaceutical industry chain, and promoting the deep integration of scientific and technological innovation and industrial innovation.